Investigator’s Brochure: BNT162/PF-07302048

BioNTech RNA Pharmaceuticals GmbH

The development of a ribonucleic acid (RNA)-based vaccine encoding a viral antigen that is translated by the vaccinated organism to protein to induce a protective immune response provides significant advantages over more conventional vaccine approaches.

At BioNTech, there are three different RNA platforms under development, namely non- modified uridine containing mRNA (uRNA), nucleoside modified mRNA (modRNA), and self-amplifying mRNA (saRNA).

BNT162 vaccine candidates based on the uRNA, modRNA, and saRNA formats are currently under investigation in three clinical trials with healthy adults (men and women) aged between 18 and 85 yrs.

Latest articles

Swiss Policy Research … data from both Germany and Switzerland does show...
Kenji Yamamoto Recently, The Lancet published a study on the effectiveness of...
Kit Knightly Polio is on the front pages of British newspapers again...
Carey Gillam Glyphosate, a synthetic herbicide patented in 1974 by the Monsanto...
Suzanne Burdick A study published last week in Environment International showed 29...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Stay up to date

Sign up to our newsletter to get the latest health-related news and events delivered straight to your inbox.

Become a CHA member

Become an active value-added member and trusted provider of medical and healthcare information and education by joining the CHA Membership Program.

Your donation helps us stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.